ResMed' half-year FY25 results: solid growth & expanding opportunities
By Roger Montgomery
ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also strategically positioned to capitalise on future growth opportunities. The company is currently at the forefront of respiratory healthcare innovation with a market capitalisation of $59 billion at $39 per share.